Table 1. Analysis of different prognostic markers from metastatic breast cancer (MBC) patients.
| Patient Number | Number of CTCs in Blood | CCT2 Score: Low (1–2), High (3–4) | ER Status | PR Status | HER2 Status | Patient Age | Number of yrs. since biopsy “Time Gap” | Number of yrs. since metastatic diagnosis |
|---|---|---|---|---|---|---|---|---|
| 020 | 1 | High | Y | N | N | 61 | 0 | 0 |
| 008 | 2 | Low | Y | Y | N | 75 | 1 | 1 |
| 012 | >5 | Low | N | N | N | 69 | 1 | 1 |
| 013 | 5 | High | Y | N | N | 71 | 1 | 11 |
| 027 | 1 | High | Y | Y | N | 48 | 1 | 1 |
| 032 | 0 | High | Y | Y | N | 51 | 1 | 1 |
| 036 | 2 | Low | N | N | Y | 40 | 1 | 1 |
| 037 | 4 | High | Y | Y | N | 57 | 1 | 0 |
| 038 | 0 | High | Y | Y | N | 70 | 1 | 1 |
| 034 | >5 | High | Y | Y | N | 62 | 2 | 1 |
| 014 | 2 | Low | N | N | N | 63 | 3 | 3 |
| 021 | 0 | Low | Y | Y | N | 57 | 3 | 3 |
| 030 | 0 | Low | Y | Y | N | 80 | 3 | 3 |
| 031 | 0 | Low | N | N | Y | 69 | 3 | 3 |
| 033 | 2 | High | Y | Y | N | 53 | 3 | 1 |
| 017 | 1 | Low | Y | Y | N | 55 | 4 | 0 |
| 019 | 1 | High | Y | Y | N | 68 | 4 | 4 |
| 023 | 4 | Low | Y | Y | N | 66 | 4 | 4 |
| 035 | 1 | Low | Y | Y | N | 50 | 5 | 0 |
| 025 | 0 | Low | NG | NG | NG | 64 | 7 | 1 |
| 018 | 1 | Low | Y | Y | N | 55 | 8 | 3 |
| 028 | 3 | Low | Y | N | Y | 33 | 9 | 4 |
| 006 | 0 | Low | Y | N | Y | 70 | 10 | 4 |
Samples 005, 007, 009, and 010 failed the screening. Samples 001, 002, 003, 004, 011, 015, 016, 022, 024, 026, and 029 were inadequate for either CTC processing or CCT2 staining. Grey highlights indicate patient specimens with five years or more time gap. The “time gap” is defined as the number of years between blood draw and a patient’s tumor biopsy. Abbreviations: NG, information not given. Y, yes. N, no.